Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423874 | 0.92 | KMT2A (0.58) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL5026966 | 0.87 | NPC1 (0.52) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL5026076 | 0.84 | MAPT (0.52) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL5024711 | 0.82 | NPC1 (0.53) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL4422399 | 0.79 | CYP1A2 (0.56) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL4421556 | 0.78 | NPC1 (0.49) | NPC1MAPTRAB9AALDH1A1ABCG2 | |
| SCHEMBL10377354 | 0.78 | NPC1 (0.49) | KMT2AMEN1NPC1MAPTRAB9A | |
| SCHEMBL4904156 | 0.76 | PDE4D (0.47) | NPC1MAPTRAB9AALDH1A1MYC | |
| SCHEMBL4898316 | 0.75 | CTSL (0.50) | ABCG2MYCWDR5PDE4DKDM4E | |
| SCHEMBL19305511 | 0.72 | KMT2A (0.85) | KMT2AMEN1RAB9ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375109-B2 | Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity | N.V. ORGANON (NL) | 2008-05-20 | — | — | US | disclosed |
| EP-1427734-B1 | GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | MERCK SHARP & DOHME B.V. (NL) | 2004-09-16 | — | — | US | disclosed |
| EP-1427734-A1 | GLYCINE-SUBSTITUTED THIENO 2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | Akzo Nobel N.V. (NL) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003020727-A1 | GLYCINE-SUBSTITUTED THIENO [2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY | AKZO NOBEL N.V. (NL) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180907-A1 | Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity | FSHR, GNRHR, LHCGR | KMT2A 980/4885MEN1 4277/4885NPC1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.